Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

New Post Hoc Analyses Examined the Effects of Neupro® (Rotigotine Transdermal System) on Daytime Functioning, Daytime Symptoms, Pain and Mood in Restless Legs Syndrome

June 10, 2011 By Bio-Medicine.Org

BRUSSELS, June 10, 2011 /PRNewswire/ — Results from new post
hoc analyses assessing the effects of Neupro® (rotigotine
transdermal system) in Restless Legs Syndrome (RLS) and utilizing
novel surrogate markers suggested improved daytime functioning and
daytime symptoms, reduced RLS-related pain and improved mood and
depressive symptoms in patients with moderate to severe RLS. The
data were presented at the 15th International Congress of
Parkinson’s disease and Movement disorders in Toronto, Canada.

Daytime functioning and daytime symptoms in RLS
patients

RLS has been mainly associated with symptoms occurring in the
late evening and at night. However, epidemiological studies and
this post hoc analysis suggested that patients may also experience
daytime symptoms and report impairment of daytime functioning.

Results of a post hoc analysis of a six month double blind study
of rotigotine transdermal in 458 patients suggested improvement in
daytime functioning and daytime symptoms in patients treated with
rotigotine transdermal (1, 2 and 3 mg/24h, pooled data) than
placebo.

“Daytime functioning symptoms, such as symptoms in the
afternoon, sleepiness and tiredness due to bad sleep are a problem
for many patients with moderate to severe RLS, and can adversely
affect their ability to carry out everyday activities. While
additional studies are needed, this post hoc analysis suggested
that patients treated with rotigotine transdermal for 6 months may
experience improvements in daytime functioning and daytime symptoms
compared to those treated with placebo. These effects may be
explained by the 24 hour coverage of symptoms, whenever they occur,
with the application of transdermal rotigotine,” said Dr. Ralf
Kohnen, University of Erlangen-Nuremberg, Germany.

Significant improvements with rotigotine transdermal versus
placebo (from baseline to end of maintenance) were seen in a series
of measures of RLS symptom severity on the I

‘/>”/>

SOURCE

Related Articles Read More >

Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A Medtronic HVAD pump opened up to show the inner workings
Medtronic investigates HVAD pump welds after patient deaths
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies

DeviceTalks Weekly.

May 13, 2022
Our Pre-Post-DeviceTalks Boston episode, also MedtronicTalks replay with Gastro CMO Austin Chiang
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech